RATIONALE: Allergy to penicillin, and related cephalosporins, is one of the most common drug allergies reported, affecting approximately 10% of patients. Despite the frequency of reported reactions, most patients are either not truly allergic or lose sensitivity over years. Unnecessary avoidance of penicillins affects quality of care and increases health care costs. Here we examine patients' history of penicillin reactions and attitudes regarding testing and outcomes of testing. METHODS: We identified adult patients presenting to our allergy/ immunology practice who reported penicillin allergy during the visit. Patients completed a survey inquiring about reaction history, subsequent antibiotic use, knowledge/beliefs about testing, and demographics. The medical record was reviewed to collect testing results, if performed. RESULTS: Twenty-two patients (18% male, mean age 47 years) participated. Nineteen (86%) reported receiving an alternative antibiotic due to penicillin allergy, including 7 patients (32%) treated for Group B Strep or syphilis. Half of patients reported awareness of testing prior to visit; 17 (77%) reported interest in testing afterward. Fourteen patients (64%) reported they would have sought evaluation sooner had they known the favorable outcomes of testing. Four patients (18%) underwent testing; three had negative skin testing and oral challenge with removal of the penicillin allergy label; one had indeterminate skin testing and declined challenge. CONCLUSIONS: Despite available testing, reports of penicillin allergy continue to be common, though most patients are likely tolerant. Mislabeling leads to unnecessary utilization of alternative antibiotics and growing resistance. Further patient education regarding the natural history of penicillin allergy and safety and importance of testing is required.
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Six-step Trimethoprim-Sulfamethoxazole Desensitization Protocol in non-HIV patients with Self-reported Sulfa Allergy: A Single Center Experience Annamaria G. Mechtler, MD, Natalia Chamorro-Pareja, MD, Ismael Carrillo-Martin, MD, Daniela Haehn, MD, and Alexei Gonzalez-Estrada, MD; Mayo Clinic Florida, Jacksonville, FL. RATIONALE: Patients allergic to sulfa-drugs are sometimes prescribed alternative medications over trimethoprim-sulfamethoxazole (TMP-SMX) despite it being first-choice in several scenarios such as Pneumocystis jirovecii pneumonia (PCP) prophylaxis, urinary tract infections, and soft tissue infections. The purpose of the study was to evaluate our experience with a six-step desensitization protocol for TMP-SMX in non-HIV patients with sulfa allergy. METHODS: We conducted a retrospective chart review of all TMP-SMX desensitizations performed between December 2014 and May 2018 in our Allergy Clinic. The demographic and prior allergic reaction data were collected for each subject. All subjects underwent a previously published 1-day 6-step TMP-SMX protocol (Pyle et al. J Allergy Clin Immunol Pract 2014). A descriptive analysis was then performed. RESULTS: Fifty-two patients were included in the study; most were women (86.5%), and white was the prevailing ethnicity (84.6%). The most common self-reported reaction was rash (55.8%) followed by hives (15.4%), and itching (13.5%). The most common indication for TMP-SMX was PCP prophylaxis (67.3%). Ninety-eight percent of subjects tolerated this protocol without adverse reactions. Only one protocol was stopped before completion after the subject developed urticaria and requested the procedure to be suspended. No severe IgE-mediated reactions were reported during desensitization. CONCLUSIONS: According to the data we have extracted from our Allergy Clinic, this is a safe desensitization protocol with a very low tendency to produce symptoms during the procedure and with a high success rate. This is in agreement to what was published by Pyle et al. and may prove to be a protocol worth of standardization.
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Developing in vitro and in vivo Models to Predict Drug-Induced Acute Allergic Adverse Reactions Zhaohua Zhou, PhD, Sujata Bupp, Uyen Hoang, and Steven Kozlowski; OBP/CDER/FDA, Silver Spring, MD. RATIONALE: All medications have the potential to produce adverse events (AEs) and such adverse events lead to significant morbidity and mortality. Lower frequency serious AEs, particularly acute allergic reactions can have life-threatening consequences and occur minutes after drug administration. These AEs have been considered significant enough to take drugs off the market. METHODS: Methods are based upon current understanding to the mechanisms of a clinical anaphylaxis, including: 1) Drug-specific IgE screening and in vitro Type 1 sensitization (drug-binding antibodies and mast cell degranulation); 2) Drug-specific IgG/IgM screening followed by complement-activation through classical and non-classical pathway-generated anaphylatoxins assay (C3a, C4a and C5a); 3) Direct mast cell degranulation; 4) Cytokine storm assays (activated T cells and macrophages using PBMC or whole blood culture); and 5) Contact system (kinin/kallikrein) activation assay. In addition, we developed a C1 inhibitor deficient mouse model to enhance the prediction of contact system-associated acute allergy in vivo. RESULTS: From the study of 2008 heparin AEs which caused hundreds of acute allergy symptoms and death to more recently, the recall of Omontys (peginesatide) which caused serious hypersensitivity reactions including anaphylaxis, our research group has established several in vitro and in vivo models to quickly pinpoint the potential cause of an acute allergic reaction. CONCLUSIONS: These in vitro and in vivo models will not only help the agency to quickly identify and respond to potential causes of drug-induced acute allergic AEs, but also better determine the likelihood and potentially mitigate the risk of acute reactions for regulated products. 1 Floridsdorf Allergy Centre (FAZ), Vienna, Austria, 2 Medical University of Vienna (MUV), Vienna, Austria, 3 Floridsdorf Allergy Center (FAZ), Vienna, Austria. RATIONALE: Many patients claim "allergy" to betalactam antibiotics, a history which is often wrong and confirmatory tests are required to rule out or confirm this. Provocation tests put patients at risk during testing, while in vitro and skin tests can be performed on a rather safe base. METHODS: We performed a retrospective review of a cohort of patient charts, who had visited the "Floridsdorfer Allergie Zentrum" (Floridsdorf allergy center (FAZ), Vienna) for a suspected penicillin or cephalosporin allergy from January 1 st , 2016 to December 31 st , 2017. A drug-specific history was obtained from all patients. Specific IgE was determined (ImmunoCAP, ThermoFisher, Penicillin G + V, Amoxycillin, Ampicillin, MDM, Cefaclor) and skin prick tests, intradermal tests and patch test (Penicillin G + V, Amoxillin, Ampicillin, Cefazolin, Cefuroxim, Ceftriaxon) were performed and read after 20 min and after 24 hours. This study was approved by the Ethic's comittee of the Medical University of Vienna, Austria. RESULTS: Of 792 patients (562 female and 232 males, average age 42.3 years +/-21-9 years SD), who were eligible for inclusion into the study, 100 had positive skin-or in vitro tests (12.62%). In detail, there were more positive immediate (42 5 5.03% skin test, 44 5 5.5.6% specific IgE) than delayed (19 5 2.40%) reactions. Specific IgE to Penicillin V was the most frequent positive single test result (27 5 3.68%). CONCLUSIONS: Skin and in vitro testing are sensitive, easy and safe tools in the confirmation of betalactam-allergy in about every 10 th patient.
